LON:BVX BiVictriX Therapeutics (BVX) Share Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About BiVictriX Therapeutics Stock (LON:BVX) 30 days 90 days 365 days Advanced Chart Remove Ads Get BiVictriX Therapeutics alerts:Sign Up Key Stats Today's Range N/A50-Day Range 10▼ 1052-Week Range N/AVolume1.54 million shsAverage Volume108,326 shsMarket Capitalization£8.25 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewBiVictriX Therapeutics Plc, a biotechnology company, engages in the development of cancer therapies in the United Kingdom. The company develops Bi-Cygni therapeutics, which are selective for cancer types. Its lead program is BVX001, focuses on acute myeloid leukaemia, as well as develops BVX002 and BVX003 for various blood cancers and solid tumours. BiVictriX Therapeutics Plc was founded in 2016 and is headquartered in Macclesfield, the United Kingdom.Read More… Remove Ads Receive BVX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BiVictriX Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address BVX Stock News HeadlinesBivictrix quits London’s AIM to chase private funding as market ‘undervalues’ firmAugust 12, 2024 | msn.comBiVictriX Therapeutics Proposes Delisting From London's AIMAugust 12, 2024 | marketwatch.com$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being carried out by the Fed that has nothing to do with lowering or raising interest rates... but could soon have an enormous impact on your wealth.April 4, 2025 | Stansberry Research (Ad)BiVictriX Therapeutics PLC (BVX)April 17, 2024 | investing.comWhen Will BiVictriX Therapeutics Plc (LON:BVX) Turn A Profit?February 15, 2024 | finance.yahoo.comBiVictriX Therapeutics' former chair moves onDecember 6, 2023 | proactiveinvestors.comBRIEF-Bivictrix Therapeutics PLC Extended Survival Rates Reported With Bvx001 In A Pre-Clinical Model Of Acute Myeloid LeukaemiaOctober 12, 2023 | reuters.comBiVictriX says latest preclincial leukaemia data could accelerate progressOctober 12, 2023 | proactiveinvestors.comSee More Headlines BVX Stock Analysis - Frequently Asked Questions How do I buy shares of BiVictriX Therapeutics? Shares of BVX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of BiVictriX Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that BiVictriX Therapeutics investors own include AutoZone (AZO), Intel (INTC), Premier African Minerals (PREM), Rolls-Royce Holdings plc (RR), TJX Companies (TJX), Abacus Health Products (ABAHF) and Aurora Cannabis (ACB). Industry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:BVX CIKN/A Webwww.bivictrix.com PhoneN/AFaxN/AEmployees17Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-2,670,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-103.99% Return on Assets-62.99% Debt Debt-to-Equity Ratio8.81 Current Ratio4.40 Quick Ratio7.49 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash Flow2.20 Book ValueGBX 3 per share Price / BookN/AMiscellaneous Outstanding Shares82,530,000Free FloatN/AMarket Cap£8.25 million OptionableNot Optionable Beta-0.73 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (LON:BVX) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BiVictriX Therapeutics Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share BiVictriX Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.